Khavinson Short-Peptide Bioregulators: Family Research Overview

This family comprises several short synthetic peptides (di-, tri-, and tetrapeptides) developed within the Khavinson 'peptide bioregulator' research program: vilon (Lys-Glu dipeptide), vesugen (reported as Lys-Glu-Asp, KED, tripeptide), cartalax (reported as Ala-Glu-Asp, AED, tripeptide), cardiogen (reported as Ala-Glu-Asp-Arg, AEDR, tetrapeptide), chonluten (reported tripeptide related to bronchial tissue extract sequences), testagen (reported as Lys-Glu-Asp-Gly, KEDG, tetrapeptide), and cortexin (a polypeptide fraction extracted from mammalian brain cortex, not a single defined short-peptide sequence). Each compound is chemically distinct and should not be treated as interchangeable; sequence assignments above reflect vendor/secondary-source reporting and are not independently confirmed against a primary structural-chemistry paper for every compound in this search.

The broader research program proposes that some short peptides influence gene expression and cell differentiation. Khavinson et al. (2021) provide a systematic review, and Anisimov and Khavinson (2010) review aging-related research. These are secondary syntheses, not proof that every named compound has the same mechanism or tissue selectivity.

Vilon: Khavinson et al. (2000) reported tumor-growth and survival findings in mice. A separate Lys-Glu lymphocyte study (2000) examined interleukin-2 gene expression. the Vilon chromatin study (2004) examined cultured lymphocytes from older donors. These are model-specific findings; a human-derived cell culture is not an administered-human longevity trial.

Vesugen: the endothelial-culture study (2014) examined proliferation-marker expression and molecular modeling. Khavinson et al. (2021) studied KED and EDR tripeptides in a mouse Alzheimer-model system. Results for particular sequences do not establish interchangeability across the full family.

Chonluten: Avolio et al. (2022) studied proliferative and inflammatory readouts in THP-1 monocyte/macrophage cell models. This is primary cell research; it does not establish lung repair or a human clinical effect.

Cartalax: the AED/related-peptide study (2016) examined aging skin-fibroblast cultures, including proliferation, apoptosis and matrix-remodeling markers. This is sequence-specific cell research, not a cartilage-regeneration result or verification of the prepared Cartalax lot. Linkova et al. (2023) separately review chondrogenic differentiation; that review is not a new primary Cartalax trial.

Testagen: Fedoreyeva et al. (2011) observed fluorescently labeled short peptides, including Testagen (Lys-Glu-Asp-Gly), in HeLa cells and studied peptide interactions with nucleic acids using fluorescence assays. Labeled-peptide localization and in vitro sequence-dependent interactions do not establish human testicular, thyroid or performance effects. Testagen and Thyramin are different substances; thyroid findings for Thyramin cannot be assigned to Testagen.

Cardiogen: the rat myocardium-culture study (2009) investigated tissue explants from young and old rats, including proliferation and p53 readouts. It does not demonstrate heart repair in living animals or people. Cortexin: the name refers to a heterogeneous cortical polypeptide fraction, not a single short synthetic sequence; Umnov et al. (2013) provide review-level context. Findings for another named peptide do not establish a Cortexin product’s identity or effect.

The primary examples have limited models and uneven independent replication. Sequence assignments that rely on secondary or label reporting remain provisional until matched to adequate structural or analytical evidence. Each prepared product needs its own exact identity and lot binding. Family-level research does not establish cross-compound or blend efficacy.